Product Description
Mechanisms of Action: COX Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Cyprus | Denmark | Dominican Republic | Egypt | France | Germany | Greece | Hong Kong | India | Indonesia | Ireland | Italy | Jordan | Korea | Lebanon | Luxembourg | Mexico | Morocco | New Zealand | Pakistan | Peru | Philippines | Portugal | Romania | Russia | Saudi Arabia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Kingdom | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|